N4 Pharma’s Nuvec® Shows Promising Results in IBD Study

N4 Pharma ( (GB:N4P) ) has provided an update.

N4 Pharma has announced positive results from its first in vivo study of the N4 101 programme, an orally delivered anti-inflammatory treatment for Inflammatory Bowel Disease (IBD) using its Nuvec® technology. The study demonstrated significant reductions in inflammation and a marked increase in efficacy when targeting specific cells, showcasing the potential of Nuvec® as a leading nucleic acid delivery technology. These findings are expected to strengthen N4 Pharma’s position in the biotech industry and enhance discussions with commercial partners as they advance the programme into further development stages.

More about N4 Pharma

N4 Pharma is a pre-clinical biotech company focused on developing Nuvec®, a proprietary gene delivery system designed to enable advanced therapies for cancer and other diseases. The company is working on building a preclinical data set and aims to achieve first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

Average Trading Volume: 1,744,751

Technical Sentiment Signal: Sell

Current Market Cap: £8M

For an in-depth examination of N4P stock, go to TipRanks’ Stock Analysis page.